Clinical Trial Update: Study of Out of Specification for Tisagenlecleucel [Phase 3]

View source ↗

Summary

This document reports a Phase 3 clinical trial update for tisagenlecleucel (Kymriah) addressing an out-of-specification issue, for indications including B-cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Kymriah (tisagenlecleucel)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma | Phase 3 | Status: RECRUITING